A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
ConditionDiabetes Mellitus, Type 2
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAmgen
About this trial
The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).
Eligibility criteria
Qualifiers
Participant must be 18-65 years of age
Participant must be overtly healthy
Participant must be 40-75 years of age
Confirmed diagnoses of T2DM
Disqualifiers
History of hypotension, syncope, or orthostatic intolerance
Systolic blood pressure >140 millimeters of mercury (mmHg) or diastolic blood pressure >90 mmHg
Hemoglobin A1c (HbA1c) >10% within the last 3 months
History of hypotension, syncope, or orthostatic intolerance
Trial design
Treatments tested in this trial
- AMG 127
- Placebo
Treatment groups
162 Participants
are divided into 4 treatment groupsLocations
1Translational Clinical Research LLC33180, AventuraFlorida, United States
Sponsors and collaborators
Amgen
Lead sponsor
Source ClinicalTrials.gov